Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 2;408(1):347.
doi: 10.1007/s00423-023-03073-2.

Prognostic factor in patient with recurrent pancreatic adenocarcinoma

Tatsuaki Sumiyoshi  1 , Kenichiro Uemura  2 , Ryuta Shintakuya  1 , Kenjiro Okada  1 , Hiroyuki Otsuka  1 , Kenta Baba  1 , Masahiro Serikawa  3 , Yasutaka Ishii  3 , Tomofumi Tsuboi  3 , Koji Arihiro  4 , Yoshiaki Murakami  5 , Jyunji Murashita  6 , Shinya Takahashi  1
Affiliations

Prognostic factor in patient with recurrent pancreatic adenocarcinoma

Tatsuaki Sumiyoshi et al. Langenbecks Arch Surg. .

Abstract

Purpose: To elucidate prognostic factors for post-recurrence survival in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: Patients who underwent curative-intent surgery for PDAC between January 2014 and May 2020 were identified. Among them, patients who had postoperative recurrences and received chemotherapy were retrospectively investigated. Independent prognostic factors for survival after recurrence were investigated using multivariate analyses. Eligible patients were divided into two groups according to the presence or absence of the identified prognostic factors, and survival times after recurrence were compared.

Results: Eighty-four patients with recurrent PDAC were included. Multivariate analysis showed that red blood cell (RBC) transfusion (HR, 2.80; p = 0.0051), low albumin level (HR, 1.84; p = 0.0402), and high carbohydrate antigen 19-9 (CA19-9) level at recurrence (HR, 2.11; p = 0.0258) were significant predictors of shorter survival after recurrence. The median survival times after recurrence in the transfusion and non-transfusion groups were 5.5 vs. 18.1 months (p < 0.0001), respectively; those in the low and normal albumin groups were 10.1 vs. 18.7 months (p = 0.0049), and those in the high and normal CA19-9 groups were 11.5 vs. 22.6 months (p = 0.0023), respectively.

Conclusions: RBC transfusion, low albumin, and high CA19-9 levels at recurrence negatively affected survival after recurrence in patients with PDAC.

Keywords: Blood transfusion; Carbohydrate antigen 19-9; Low albumin; Pancreatic adenocarcinoma; Recurrence.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30 - PubMed
    1. Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257 - PubMed
    1. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277 - PubMed
    1. Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M et al (2018) Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open 2:52–61 - PubMed - PMC
    1. Seelen LWF, Floortje van Oosten A, Brada LJH, Groot VP, Daamen LA, Walma MS et al (2023) Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study. Ann Surg 278:118–126 - PubMed

LinkOut - more resources